What are the critical protein expression changes and post-translational modifications (phosphorylation, ubiquitination, glycosylation) at the aging synapse that drive early Alzheimer disease pathophysiology? Focus on: (1) synaptic vesicle proteins and their PTM states, (2) scaffold proteins and their altered interactions, (3) receptor tyrosine kinase signaling cascades, (4) mitochondrial proteins at the synapse, and (5) proteins involved in amyloid precursor protein processing. How do these proteomic changes correlate with cognitive decline and which represent therapeutic intervention points?
Age-dependent p35-to-p25 cleavage activates Cdk5, which phosphorylates PSD-95 S561, disrupting AMPA/NMDA receptor anchoring and recruiting ubiquitin ligases that degrade ADAM10, thereby redirecting APP processing toward amyloidogenic β-secretase cleavage.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Age-Dependent Calpain Activation p35 Cleavage to p25"]
B["Cdk5/p25 Hyperactivation Aberrant Kinase Activity"]
C["PSD-95 DLG4 Ser561 Phosphorylation Scaffold Protein Destabilized"]
D["AMPA NMDA Receptor Uncoupling Synaptic Density Protein Loss"]
E["Ubiquitin Ligase Recruitment ADAM10 Protease Degradation"]
F["APP Processing Redirected BACE1 over ADAM10 alpha-Secretase"]
G["Amyloid-Beta Generation Increased Synaptic Plaque Nucleation"]
H["Synapse Loss and AD Progression Cognitive Decline"]
A --> B
B --> C
C --> D
C --> E
E --> F
F --> G
D --> H
G --> H
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID5 mediumValidation: 43%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-12 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: Synaptic Proteomic Changes in Early Alzheimer Disease Pathophysiology
Title: PSD-95 S561 Phosphorylation Links Synaptic Failure to APP Processing
Mechanism: Age-dependent activation of cyclin-dependent kinase 5 (Cdk5), likely through calpain-mediated p35 cleavage to p25, leads to pathological phosphorylation of PSD-95 at serine 561. This modification disrupts PSD-95's PDZ domain interactions with AMPA receptor subunits (GRIA1-4) and NMDA
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic's Evaluation: Synaptic Proteomic Hypothesis in Early Alzheimer Disease
Overall Framing Assessment
Before evaluating individual hypotheses, a structural concern must be raised: the research question proposes five distinct proteomic domains, but only one mechanistic hypothesis is presented. This evaluation must assess what exists. The remaining domains—synaptic vesicle proteins, scaffold interactions, RTK signaling, mitochondrial proteins, and APP processing—lack corresponding hypotheses, making the request internally inconsistent. I'll evaluate what is provided and flag wh
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain Expert Evaluation: Synaptic Proteomic Hypotheses in Early Alzheimer Disease
Executive Summary
The research question addresses a critical and underexplored frontier in Alzheimer's disease (AD) pathophysiology: the proteomic architecture of the aging synapse as a proximal driver of early AD neurodegeneration. I will evaluate the presented hypothesis, construct interpretable frameworks for the four missing domains, identify the highest-translational opportunities, address the Skeptic's mechanistically sound critique, and propose an underappreciated mechanism worthy of investigatio
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for PSD-95 (DLG4).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
IF primary cortical neurons from APP knock-in mice express p25 (but not p35) via viral transduction for 48-72 hours, THEN PSD-95 S561 phosphorylation will increase, AMPA/NMDA receptor surface expression will decrease, and Aβ40/42 secretion will increase, using murine primary neuronal cultures transduced with AAV-p25 or AAV-p35
pendingconf: 0.78
Expected outcome: p25 expression will cause ≥50% increase in PSD-95 S561 phosphorylation, ≥30% reduction in surface GluA1 and GluN1, and ≥40% increase in secreted Aβ40/42 compared to p35-expressing or uninfected controls
Falsified by: This hypothesis would be disproven if p25 expression does NOT increase PSD-95 S561 phosphorylation, or if Aβ secretion remains unchanged despite elevated p25 levels, indicating Cdk5/p25 acts through a PSD-95-independent mechanism
Method: AAV-mediated gene delivery of p25 or p35 to DIV14 primary neurons from App^NL-G-F/NL-G-F knock-in mice; measure PSD-95 S561 phosphorylation by phospho-specific immunoblot, surface receptor levels by biotinylation assay, and Aβ by ELISA at 48-72h post-transduction
IF neurons express phospho-mimetic PSD-95 S561D mutant (which cannot be phosphorylated by Cdk5) THEN ADAM10 protein levels and sAPPα secretion will remain stable, whereas wild-type PSD-95 with p25 co-expression will trigger ADAM10 degradation and reduce sAPPα, using human iPSC-derived cortical neurons
pendingconf: 0.72
Expected outcome: The S561D mutant will show: (1) no change in ADAM10 levels vs. baseline, (2) sAPPα secretion at baseline levels, (3) no increase in C99/CTFβ, whereas wild-type PSD-95 + p25 will show ≥50% ADAM10 loss, ≥40% sAPPα reduction, and ≥60% C99 increase
Falsified by: This hypothesis would be disproven if the phospho-mimetic S561D mutant also triggers ADAM10 degradation and reduces sAPPα, demonstrating that S561 phosphorylation is NOT the critical signal for recruiting ubiquitin ligases to ADAM10
Method: Lentiviral transduction of human iPSC-derived cortical neurons with PSD-95 WT or S561D; co-infect with p25 or vector control; measure ADAM10 protein by immunoblot, sAPPα by ELISA, C99/CTFβ by immunoblot, and synaptic function by whole-cell patch clamp at 5-7 DIV post-infection
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
PSD-95 — Search for structure
Click to search RCSB PDB